{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:45:26Z","timestamp":1791254726574,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"43","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005624","name":"PATH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005624","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.vaccine.2021.09.024","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T18:58:00Z","timestamp":1632769080000},"page":"6398-6406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["A phase IIA extension study evaluating the effect of booster vaccination with a fractional dose of RTS,S\/AS01E in a controlled human malaria infection challenge"],"prefix":"10.1016","volume":"39","author":[{"given":"James E.","family":"Moon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa E.","family":"Greenleaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Regules","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Debois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth H.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Sedegah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilin","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2615-7420","authenticated-orcid":false,"given":"Cynthia K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April K.","family":"Sikaffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey S.","family":"Garver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1279-2458","authenticated-orcid":false,"given":"Karen","family":"Ivinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelina","family":"Angov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Morelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Lievens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian F.","family":"Ockenhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viseth","family":"Ngauy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Opokua","family":"Ofori-Anyinam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.09.024_b0005","unstructured":"World Health Organization (WHO). World malaria report 2020: 20 years of global progress and challenges. 2020. Available at: https:\/\/www.who.int\/publications\/i\/item\/9789240015791. Last accessed on 23 January 2021."},{"key":"10.1016\/j.vaccine.2021.09.024_b0010","unstructured":"World Health Organization (WHO). 2013 Update to the Malaria Vaccine Technology Roadmap. 2013. Available at: https:\/\/www.who.int\/immunization\/sage\/meetings\/2013\/april\/6_Draft_roadmap_update_v_5_March.pdf?ua=1. Last accessed on 23 January 2021."},{"key":"10.1016\/j.vaccine.2021.09.024_b0015","doi-asserted-by":"crossref","unstructured":"Rabinovich RN, Drakeley C, Djimde AA, Hall BF, Hay SI, Hemingway J, et al. malERA: An updated research agenda for malaria elimination and eradication. PLoS Med. 2017;14:e1002456. 10.1371\/journal.pmed.1002456.","DOI":"10.1371\/journal.pmed.1002456"},{"key":"10.1016\/j.vaccine.2021.09.024_b0020","unstructured":"World Health Organization (WHO). Malaria vaccine implementation programme (MVIP) - Programme Advisory Group. Available at: https:\/\/www.who.int\/immunization\/research\/committees\/malaria_vaccine_implementation_group\/en\/. Last accessed on 5 February 2021."},{"key":"10.1016\/j.vaccine.2021.09.024_b0025","doi-asserted-by":"crossref","unstructured":"RTS,S Clinical Trials Partnership. First results of phase 3 trial of RTS,S\/AS01 malaria vaccine in African children. N Engl J Med. 2011;365:1863-75. 10.1056\/NEJMoa1102287.","DOI":"10.1056\/NEJMoa1102287"},{"key":"10.1016\/j.vaccine.2021.09.024_b0030","doi-asserted-by":"crossref","unstructured":"RTS,S Clinical Trials Partnership. Efficacy and safety of the RTS,S\/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 2014;11:e1001685. 10.1371\/journal.pmed.1001685.","DOI":"10.1371\/journal.pmed.1001685"},{"key":"10.1016\/j.vaccine.2021.09.024_b0035","doi-asserted-by":"crossref","unstructured":"RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386:31-45. 10.1016\/s0140-6736(15)60721-8.","DOI":"10.1016\/S0140-6736(15)60721-8"},{"key":"10.1016\/j.vaccine.2021.09.024_b0040","doi-asserted-by":"crossref","unstructured":"Regules JA, Cicatelli SB, Bennett JW, Paolino KM, Twomey PS, Moon JE, et al. Fractional third and fourth dose of RTS,S\/AS01 malaria candidate vaccine: A phase 2a controlled human malaria parasite infection and immunogenicity study. J Infect Dis. 2016;214:762-71. 10.1093\/infdis\/jiw237.","DOI":"10.1093\/infdis\/jiw237"},{"key":"10.1016\/j.vaccine.2021.09.024_b0045","unstructured":"Moon JE, Ockenhouse C, Regules JA, Vekemans J, Lee C, Chuang I, et al. A phase IIa controlled human malaria infection and immunogenicity study of RTS,S\/AS01E and RTS,S\/AS01B delayed fractional dose regimens in malaria-naive adults. J Infect Dis. 2020;222:1681-91. 10.1093\/infdis\/jiaa421."},{"key":"10.1016\/j.vaccine.2021.09.024_b0050","doi-asserted-by":"crossref","unstructured":"Gar\u00e7on N, Heppner DG, Cohen J. Development of RTS,S\/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev Vaccines. 2003;2:231-8. 10.1586\/14760584.2.2.231.","DOI":"10.1586\/14760584.2.2.231"},{"key":"10.1016\/j.vaccine.2021.09.024_b0055","doi-asserted-by":"crossref","unstructured":"Alderson MR, McGowan P, Baldridge JR, Probst P. TLR4 agonists as immunomodulatory agents. J Endotoxin Res. 2006;12:313-9. 10.1179\/096805106x118753.","DOI":"10.1179\/096805106X118753"},{"key":"10.1016\/j.vaccine.2021.09.024_b0060","doi-asserted-by":"crossref","unstructured":"Kensil CR, Kammer R. QS-21: a water-soluble triterpene glycoside adjuvant. Expert Opin Investig Drugs. 1998;7:1475-82. 10.1517\/13543784.7.9.1475.","DOI":"10.1517\/13543784.7.9.1475"},{"key":"10.1016\/j.vaccine.2021.09.024_b0065","doi-asserted-by":"crossref","unstructured":"Gordon DM, McGovern TW, Krzych U, Cohen JC, Schneider I, LaChance R, et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis. 1995;171:1576-85. 10.1093\/infdis\/171.6.1576.","DOI":"10.1093\/infdis\/171.6.1576"},{"key":"10.1016\/j.vaccine.2021.09.024_b0070","doi-asserted-by":"crossref","unstructured":"Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med. 1997;336:86-91. 10.1056\/nejm199701093360202.","DOI":"10.1056\/NEJM199701093360202"},{"key":"10.1016\/j.vaccine.2021.09.024_b0075","doi-asserted-by":"crossref","unstructured":"Tamminga C, Sedegah M, Regis D, Chuang I, Epstein JE, Spring M, et al. Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS One. 2011;6:e25868. 10.1371\/journal.pone.0025868.","DOI":"10.1371\/journal.pone.0025868"},{"key":"10.1016\/j.vaccine.2021.09.024_b0080","doi-asserted-by":"crossref","unstructured":"Clement F, Dewar V, Van Braeckel E, Desombere I, Dewerchin M, Swysen C, et al. Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum. Malar J. 2012;11:384. 10.1186\/1475-2875-11-384.","DOI":"10.1186\/1475-2875-11-384"},{"key":"10.1016\/j.vaccine.2021.09.024_b0085","doi-asserted-by":"crossref","unstructured":"Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S\/AS01B and RTS,S\/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis. 2009;200:337-46. 10.1086\/600120.","DOI":"10.1086\/600120"},{"key":"10.1016\/j.vaccine.2021.09.024_b0090","doi-asserted-by":"crossref","unstructured":"Schwenk R, DeBot M, Porter M, Nikki J, Rein L, Spaccapelo R, et al. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice. PLoS One. 2014;9:e111020. 10.1371\/journal.pone.0111020.","DOI":"10.1371\/journal.pone.0111020"},{"key":"10.1016\/j.vaccine.2021.09.024_b0095","doi-asserted-by":"crossref","unstructured":"Doba\u00f1o C, Sanz H, Sorgho H, Dosoo D, Mpina M, Ubillos I, et al. Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S\/AS01E malaria vaccine efficacy. Nat Commun. 2019;10:2174. 10.1038\/s41467-019-10195-z.","DOI":"10.1038\/s41467-019-10195-z"},{"key":"10.1016\/j.vaccine.2021.09.024_b0100","doi-asserted-by":"crossref","unstructured":"Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, Msham S, et al. Efficacy of RTS,S\/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis. 2011;11:102-9. 10.1016\/s1473-3099(10)70262-0.","DOI":"10.1016\/S1473-3099(10)70262-0"},{"key":"10.1016\/j.vaccine.2021.09.024_b0105","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.51889","article-title":"A delayed fractionated dose RTS,S AS01 vaccine regimen mediates protection via improved T follicular helper and B cell responses","volume":"9","author":"Pallikkuth","year":"2020","journal-title":"Elife."},{"key":"10.1016\/j.vaccine.2021.09.024_b0110","doi-asserted-by":"crossref","unstructured":"Suscovich TJ, Fallon JK, Das J, Demas AR, Crain J, Linde CH, et al. Mapping functional humoral correlates of protection against malaria challenge following RTS,S\/AS01 vaccination. Sci Transl Med. 2020;12. 10.1126\/scitranslmed.abb4757.","DOI":"10.1126\/scitranslmed.abb4757"},{"key":"10.1016\/j.vaccine.2021.09.024_b0115","unstructured":"ClinicalTrials.gov. Efficacy, safety and immunogenicity study of GSK Biologicals' candidate malaria vaccine (SB257049) evaluating schedules with or with-out fractional doses, early dose 4 and yearly doses, in children 5-17 months of age. Available at: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03276962?term=NCT03276962.&draw=2&rank=1. Last accessed on 23 January 2021."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21012032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21012032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:02:47Z","timestamp":1759402967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21012032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":23,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0264410X21012032"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.09.024","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase IIA extension study evaluating the effect of booster vaccination with a fractional dose of RTS,S\/AS01E in a controlled human malaria infection challenge","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.09.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}